Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats.
BPC 157
Budd Chiari syndrome
Portal/caval hypertension
Journal
World journal of gastrointestinal pathophysiology
ISSN: 2150-5330
Titre abrégé: World J Gastrointest Pathophysiol
Pays: United States
ID NLM: 101547471
Informations de publication
Date de publication:
13 Mar 2020
13 Mar 2020
Historique:
received:
07
10
2019
revised:
20
12
2019
accepted:
19
01
2020
entrez:
1
4
2020
pubmed:
1
4
2020
medline:
1
4
2020
Statut:
ppublish
Résumé
Recently, as a possible therapy resolving solution, pentadecapeptide BPC 157 therapy, has been used in alleviating various vascular occlusion disturbances. BPC 157 was previously reviewed as novel mediator of Robert cytoprotection and endothelium protection in the stomach, and gut-brain axis, beneficial therapy in gastrointestinal tract, with particular reference to vascular recruitment, ulcerative colitis and tumor cachexia, and other tissues healing. Here we raised new hypothesis about BPC 157 therapy in the Budd-Chiari syndrome in rats, rapid bypassing of the suprahepatic inferior caval vein occlusion, and rats recovery with the active and effective pharmacotherapy treatment. To investigate Budd-Chiari syndrome model (inferior caval vein suprahepatic occlusion) resolution, since BPC 157 resolves various rat vascular occlusion. We assessed the activated bypassing pathways between the inferior and superior caval veins and portocaval shunt, counteracted caval/portal hypertension, aortal hypotension, venous/arterial thrombosis, electrocardiogram disturbances, liver and gastrointestinal lesions ( BPC 157 counteracted increased P wave amplitude, tachycardia and ST-elevation, BPC 157 counteracts Budd Chiari syndrome in rats.
Sections du résumé
BACKGROUND
BACKGROUND
Recently, as a possible therapy resolving solution, pentadecapeptide BPC 157 therapy, has been used in alleviating various vascular occlusion disturbances. BPC 157 was previously reviewed as novel mediator of Robert cytoprotection and endothelium protection in the stomach, and gut-brain axis, beneficial therapy in gastrointestinal tract, with particular reference to vascular recruitment, ulcerative colitis and tumor cachexia, and other tissues healing. Here we raised new hypothesis about BPC 157 therapy in the Budd-Chiari syndrome in rats, rapid bypassing of the suprahepatic inferior caval vein occlusion, and rats recovery with the active and effective pharmacotherapy treatment.
AIM
OBJECTIVE
To investigate Budd-Chiari syndrome model (inferior caval vein suprahepatic occlusion) resolution, since BPC 157 resolves various rat vascular occlusion.
METHODS
METHODS
We assessed the activated bypassing pathways between the inferior and superior caval veins and portocaval shunt, counteracted caval/portal hypertension, aortal hypotension, venous/arterial thrombosis, electrocardiogram disturbances, liver and gastrointestinal lesions (
RESULTS
RESULTS
BPC 157 counteracted increased P wave amplitude, tachycardia and ST-elevation,
CONCLUSION
CONCLUSIONS
BPC 157 counteracts Budd Chiari syndrome in rats.
Identifiants
pubmed: 32226643
doi: 10.4291/wjgp.v11.i1.1
pmc: PMC7093306
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-19Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors state that they have no conflicts of interest.
Références
Neurosci Bull. 2019 Feb;35(1):167-170
pubmed: 30116973
Eur J Pharmacol. 2013 Feb 15;701(1-3):203-12
pubmed: 23220707
Curr Neuropharmacol. 2016;14(8):857-865
pubmed: 27138887
World J Gastroenterol. 2006 Nov 7;12(41):6577-84
pubmed: 17075968
Inflammopharmacology. 2017 May 17;:
pubmed: 28516373
Life Sci. 2017 Oct 1;186:66-79
pubmed: 28797793
J Gastroenterol Hepatol. 2008 Oct;23(10):1561-6
pubmed: 19120847
J Physiol Paris. 2001 Jan-Dec;95(1-6):289-93
pubmed: 11595452
Eur J Pharmacol. 2019 Oct 15;861:172593
pubmed: 31401154
PLoS One. 2016 Jan 06;11(1):e0141159
pubmed: 26734934
World J Gastroenterol. 2018 Dec 28;24(48):5462-5476
pubmed: 30622376
J Appl Physiol (1985). 2011 Mar;110(3):774-80
pubmed: 21030672
Eur J Pharmacol. 2016 Dec 15;793:56-65
pubmed: 27815173
Curr Med Chem. 2012;19(1):126-32
pubmed: 22300085
Eur J Pharmacol. 1997 Jul 30;332(1):23-33
pubmed: 9298922
Drug Des Devel Ther. 2015 Apr 30;9:2485-99
pubmed: 25995620
J Hepatol. 1999 Mar;30(3):433-9
pubmed: 10190726
Regul Pept. 2013 Feb 10;181:50-66
pubmed: 23327997
Curr Pharm Des. 2014;20(7):1121-5
pubmed: 23782145
Exp Ther Med. 2018 Dec;16(6):5227-5235
pubmed: 30542478
Vascul Pharmacol. 2018 Jul;106:54-66
pubmed: 29510201
J Physiol Paris. 1999 Dec;93(6):505-12
pubmed: 10672997
Curr Pharm Des. 2018;24(18):1990-2001
pubmed: 29879879
J Physiol Paris. 2001 Jan-Dec;95(1-6):303-8
pubmed: 11595454
Arq Bras Cir Dig. 2014 Nov-Dec;27(4):280-4
pubmed: 25626939
J Physiol Pharmacol. 2009 Dec;60 Suppl 7:161-5
pubmed: 20388960
Curr Pharm Des. 2011;17(16):1612-32
pubmed: 21548867
Cell Tissue Res. 2019 Aug;377(2):153-159
pubmed: 30915550
Curr Pharm Des. 2014;20(7):1126-35
pubmed: 23755725
Am J Surg. 1992 Jan;163(1):137-42; discussion 142-3
pubmed: 1733362
Curr Pharm Des. 2013;19(1):76-83
pubmed: 22950504
World J Gastroenterol. 2009 Aug 28;15(32):4049-54
pubmed: 19705502
Eur J Pharmacol. 2007 Sep 10;570(1-3):212-21
pubmed: 17628536
PLoS One. 2016 Sep 14;11(9):e0162590
pubmed: 27627764
Life Sci. 2011 Mar 14;88(11-12):535-42
pubmed: 21295044
J Physiol Pharmacol. 2010 Apr;61(2):241-50
pubmed: 20436226
World J Hepatol. 2010 Jun 27;2(6):208-20
pubmed: 21160999
Gut Liver. 2020 Mar 15;14(2):153-167
pubmed: 31158953
Am J Transplant. 2011 Nov;11(11):2342-52
pubmed: 21831159
Molecules. 2014 Nov 19;19(11):19066-77
pubmed: 25415472
Inflammopharmacology. 2017 Apr;25(2):255-264
pubmed: 28255738
Eur J Pharmacol. 2019 Mar 15;847:130-142
pubmed: 30690000
J Pharmacol Sci. 2004 May;95(1):19-26
pubmed: 15153646
Curr Pharm Des. 2017;23(27):4012-4028
pubmed: 28228068
Mayo Clin Proc. 1990 Jan;65(1):51-5
pubmed: 2296212
Hepatology. 1999 Dec;30(6):1481-9
pubmed: 10573528
J Mol Med (Berl). 2017 Mar;95(3):323-333
pubmed: 27847966
Curr Pharm Des. 2018;24(18):1947-1956
pubmed: 29898649
J Physiol Paris. 1997 May-Oct;91(3-5):139-49
pubmed: 9403788
Curr Pharm Des. 2010;16(10):1224-34
pubmed: 20166993
Life Sci. 1993;53(18):PL291-6
pubmed: 7901724
HPB Surg. 1993 Aug;6(4):331-3
pubmed: 8217931
J Physiol Pharmacol. 2009 Dec;60 Suppl 7:107-14
pubmed: 20388953
World J Gastroenterol. 2017 Dec 28;23(48):8465-8488
pubmed: 29358856
Eur J Pharmacol. 2011 Sep 30;667(1-3):322-9
pubmed: 21645505
Regul Pept. 2009 Aug 7;156(1-3):83-9
pubmed: 19465062
Curr Pharm Des. 2018;24(18):1972-1989
pubmed: 29998800
Plast Reconstr Surg. 1998 Jan;101(1):147-54
pubmed: 9427928
J Physiol Paris. 2001 Jan-Dec;95(1-6):315-24
pubmed: 11595456
World J Gastroenterol. 2017 Aug 7;23(29):5304-5312
pubmed: 28839430
World J Gastroenterol. 2018 Dec 21;24(47):5366-5378
pubmed: 30598581